$599

Novartis Post-ACC CV Investor Event Highlights; Inclisiran Expected as Class 2 Review

Today, Novartis hosted a post-ACC cardiovascular investor event in which it provided updates across its business, including Entresto, Leqvio (inclisiran), and pelacarsen (Lp(a)). Below, FENIX provides highlights and insights from the event including thoughts on inclisiran receiving a Class 2 review.

This content is for members only.
Register
Already a member? Log in here